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ABSTRACT
Repeated treatment with the non-selective dopamine agonist apomorphine results in
behavioral sensitization and enhanced dopamine synthesis in dopamine projection fields. To
examine _the role of D1-type dopamine receptors in modulating these effects, the present experiment
assessed the effects of repeated treatment with the D1-type agonist quinpirole on locomotor activity
and dopamine synthesis. In the first experiment, rats were treated with vehicle or one' of two doses
(0.3 or 3.0 mg/kg) of quinpirole for 8 days. Daily measures of locomotor activitY revealed an
initial suppression of activity produced by quinpirole which dissipated over the 8 days of treatment
(i.e., tolerance). A trend for an increase in activity for 3.0 mg/kg quinpirole compared to vehicle
was obtained on day 8. Twenty-four hours after cessation of treatment, dopamine synthesis,
measured as accumulation of 3,4-dihydroxyphenylalanine (DOPA) after treatment with the DOPA
decarboxylase inhibitor NSD-1015, was enhanced in the striatum, but not nucleus accumbens. olfactory tubercle (NAOT) or ventral mesencephalon (VM). In Experiment 2, rats were treated for
8 days with vehicle, 3.0 mg/kg quinpirole or the Dl antagonist SCH 23390 (0.5 mg/kg) in a 2
(vehicle or quinpirole) x 2 (vehicle or SCH 23390) design. Quinpirole-alone treatment resulted in
tolerance to the locomotor suppressant effects of the drug. SCH 23390-alone and quinpirole-SCH
23390 combined treatment resulted in decreased activity compared to the vehicle control group that
did not change across days. DOPA accumulation was enhanced in the striatum and NAOT after
quinpirole treatment; however, SCH 23390 had no effect In Experiment 3, rats were. treated for 10
days with vehicle, 3.0 mg/kg quinpirole or the D2 antagonist eticlopride (1.0 mg/kg) in a 2 (vehicle
or quinpirole) x 2 (vehicle or eticlopride) design. As in the first two experiments, repeated
quinpirole-alone treatment resulted in locomotor activity tolerance; however, locomotor activity in
this group was enhanced compared to vehicle controls on day 10. Eticlopride-alone and eticlopridequinpirole treated rats had suppressed locomotor activity across the 10 days. DOPA a~cumulation
was enhanced by both repeilted quinpirole and repeated eticlopride treatment in the striatum and
NAOT. DOPA accumulation in eticlopride-quinpirole treated rats was not different from vehicle
control levels in the NAOT, while no significant difference was obtained between the eticlopridealone and eticlopride-quinpirole groups in the striatum. The locomotor activity data suggest that
repeated quinpirole treatment results in tolerance to the locomotor suppressant effect of the drug.
Evidence for sensitization was obtained in two out of three of the experiments. These results
suggest that enhanced dopamine synthesis after repeated non-selective dopamine agonist treatment
is m~dulated by D1-type dopamine receptors.

KEY WORDS: Behavioral sensitization, 3,4-dihydroxyphenylalanine (DOPA), SCH
23390,
,Eticlopride, Nigrostriatal pathway, Mesolirnbic pathway
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INTRODUCTION
Drugs that act as·direct or indirect agonists for dopamine receptors often produce a
progressive enhancement of the acute behavioral effects of the drugs following repeated treatment
This phenomenon is termed "behavioral sensitization" and has been demonstrated with a variety of
dopamine agonists such as amphetamine (Kalivas and Stewart, 1991; Robinson and Becker,
1986), cocaine (Kalivas and Stewart, 1991; Zahniser et al., 1988) and apomorphine:(Castro et al.,
1985; Mattingly et al, 1988a,b). Available evidence indicates that changes in the nigrostriatal and
mesolimbic dopamine systems may underlie behavioral sensitization (Kalivas and Stewart, 1991;
Robinson and Becker, 1986; Rowlett et al., 1991). The precise mechanism of the neurobiological
alteration accounting for sensitization is not known. In general, the data suggest changes in
presynaptic dopamine function (Kalivas and Stewart, 1991; Rowlett et al., 1993) and/or nondopamine systems involved in feedback to the dopamine systems (Kalivas and Stewart, 1991;
Karler et al., 1991). Nonetheless, a critical factor in the development of sensitization to dopamine
agonists is dopamine receptor stimulation (Kuczenski and Leith, 1981; Mattingly and Rowlett,
1989; Peris and Zahniser, 1989), suggesting that alterations in the dopamine receptor system also
may be involved in this phenomenon.
Recently, we have examined the role of dopamine receptor subtype stimulation in the
development of locomotor sensitization following daily injections of the non-selective dopamine
agonist-apomorphine. Our results show that co-administration of the selective Di-type receptor
antagonist SCH 23390 with repeated apomorphine prevents the development of locomotor
sensitization (Mattingly et al, 1991). In contrast, co-administration of the D1-type receptor
antagonist sulpiride does not prevent locomotor sensitization to apomorphine, despite sulpiride's
ability to block the acute locomotor-activating effects of apomorphine (Mattingly et al., 1991).
Further, daily injections of the Di-selective agonist SKF 38393 results in locomotor sensitization
to a subsequent challenge of apomorphine (Mattingly et al, 1993). Repeated treatment with
quinpirole, a D1-type agonist with greater affinity for the D3 versus D2 subtypes (Sokoloff et al.,
1990), also results in locomotor sensitization following apomorphine challenge (Mattingly et al.,
1993). However, this effect of repeated quinpirole treatment is blocked by co-administration of
SCH 23390. Taken together, these findings indicate a critical role for Di-type receptor stimulation
in the development of locomotor sensitization to apoinorphine.
To date, the only neurochernical change consistently found after repeated apomorpltlne
treatment is enhanced dopamine synthesis in dopamine terminal fields 24 hours after the cessation
of repeated treatment (Rowlett et al., 1991, 1993; Vaughn et al., 1990). Because behavior.al
evidence strongly suggests a role for D1-type receptors in the modulation of sensitization to
apomorphine, we previously assessed the role of Di-type receptor stimulation in ~s enhanced
dopamine synthesis effect (Rowlett et al.; 1993). Repeated treatment with SKF 38393 either
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slightly decreased or had no effect on dopamine synthesis in dopamine projection fields or cell
body regions, indicating that Di-type receptors do not exclusively regulate enhanced dopamine
synthesis following repeated apomorphine treatment The lack of involvement of Di-type receptors
in the enhanced dopamine synthesis effect suggests that this neurochemical finding may not be
'
directly tied to the development of locomotor sensitization modulated by repeated Di stimulation.
Available evidence indicates that Dz-type autoreceptors, rather than Di-type receptors,
regulate dopamine synthesis (Brown et al., 1985; Wachtel et al., 1989; White and Waiig. 1984b;
Wolf and Roth, 1990). In addition, autoreceptors may include D3 dopamine receptors (Schwartz et
al., 1993). Thus, the enhanced dopamine synthesis effect observed after repeated apomorphine
treatment may reflect a reduction in Dz and/or D3 autoreceptor sensitivity. Indeed,
electrophysiological studies have provided evidence for autoreceptor subsensitivity following either
repeated apomorphine (Jeziorski and White, 1989; Rebec and Lee, 1982) or indirect dopamine
. agonist treatment (Henry et al., 1989; White and Wang, 1984a; Wolf et al., 1993). The present
study assessed the role of mixed Dz and D3 receptor stimulation in the development of enhanced
dopamine synthesis. Rats were given daily injections of quinpirole and dopamine synthesis was
measured as accumulation of 3,4-dihydroxyphenylalanine (DOPA) after DOPA decarboxylase
inhibition. The role of dopamine receptot subtype stimulation was further assessed by coadrninistering quinpirole-treated rats with the Di-type antagonist SCH 23390 or the D:i-type
antagonist eticlopride. We assessed dopamine synthesis in the major projection fields of the
nigrostriatal and mesolimbic dopamine pathways: the striatum and nucleus accumbens-olfactory
tubercle (NAO'D, respectively. In addition, we assessed dopamine synthesis in the cell body
regions of both the nigrostriatal and mesolirnbic system (ventral mesencephalon, VM), an area
implicated in the development of sensitization (Kalivas and Stewart, 1991). Locomotor behavior
was assessed during the repeated treatment phase of each experiment.
MATERIALS AND METHODS

Subjects
Male Wistar albino rats (250-300 g, Harlan Industries, Indianapolis) were used in each
experiment All rats were housed individually in a colony room (artificial lighting from 07.00 to
19.00 h) and maintained with food and water available continuously. Behavioral testing and brain
tissue collection were conducted during the light phase of the cycle.
Locomotor activity apparatus
Activity measures were taken in two Model 145-03 BRS/Lehigh Valley cylindrical activity
. drums as described previously (Mattingly et al., 1988a; Rowlett et al., 1993). Briefly; each activity
drum had two banks of three infrared photocells mounted on the wall of the drum (60, cm diameter,
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43 cm high). Movement of the rat through a photocell beam was quantified as a single "count"
recorded by electromechanical equipment in an adjoining room. Simultaneous pulses (i.e., spaced
less than 0.05 s apart), such as might occur when two beams were broken near their intersection,
were recorded as a single count by this method. Thus, activity was defined as the cu~ulative
number of photobeam interruptions per unit of time.
Tissue dissections and assay for DOPA
For tissue dissections, rats were killed by rapid decapitation and the brains were removed
and placed on an ice-cold dissection plate. Striatal and mesolimbic (nucleus accumbens and
olfactory tubercle.combined, NA01) samples were dissected from a coronal slice that extended
from approximately 2-3 mm anterior to bregma (Paxinos and Watson, 1986). Tue ventral
mesencephalon (VM) was dissected similar to that diagrammed previously for the substantia nigra
· (Westerink and Korf, 1976), except that the AlO cell bodies were also included. Each sample was
weighed and placed in 0.1 M HCl04 (100 mg/ml for the striatum and NAOT, 50 mg/ml for the
VM) and stored at -1ooc.
(

On the day of the assay, the tissue samples were thawed and sonicated (Vibracell, setting
80). Tue tissue homogenates then were centrifuged at 30,000 X g for 15 min (40C). Supernatants
(20 ul) were injected into one of two high-performance liquid chromatograph (HPLC) systems.
One system consisted ofBioanalytical Systems LC-304T electrochemical detector (working
electrode= +750 mV against the Ag/AgCl reference electrode),. PM-11 pump and a temperaturecontrolled column (25°C, 5 µm). Tue mobile phase for this system consisted of 50 mM Na2HP04,
124 mM citric acid, 0.1 mM EDTA, 0.03% (w/v) sodium octyl sulfate and 10% (v/v) methanol
(pH 3.0). Tue second system consisted of a Bioanalytical Systems LC4B electrochemical detector
(working electrode= +750 mV against the Ag/AgCl reference electrode), PM-11 pump and a
temperature-controlled coliimn (35°C, 3 µm). Tue mobile phase for this system consisted of 50
mM Na2HP04, 124 mM citric acid, 0.1 mM EDTA and 10% methanol (pH 3.0). Tue amount of
DOPA was determined by comparison with the peak heights of DOPA standards, which were
assayed daily. Peak identity was verified by retention times and by sometimes spiking a tissue
sample with a small amount of DOPA standard.

.

Drugs
Quinpirole HCl, SCH 23390 HCl and eticlopride HCl (Research Biochemicals) were
mixed in distilled water and injected SC in a volume of 1.0 ml/kg. Tue DOPA decarboxylase
inhibitor NSD-1015 (M-hydroxybeiizylhydrazine dihydrochloride, Sigma) was dissolved daily in
distilled water at a volume of 1.0 ml/kg and injected IP. DOPA standards (Research Biochemicals)
were mixed in 0.1 M H004.
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Procedures
Experiment 1
At the beginning of the experiment, 39 rats were randomly assigned to one of three
treatment groups (n=l3/group): 0 (vehicle), 0.3 or 3.0 mg/kg quinpirole. On each of the first 8
days of the experiment, the rats were injected with the appropriate dose of quinpirole'and .then
tested for locomotor activity 15 minutes after the injection. Locomotor activity was mea.sured for
20 minutes each day. On day 9, all rats were injected with 100 mg/kg NSD-1015 and were
sacrificed 30 minutes later (no activity measures were taken on this day).

Experiments 2 and 3
For both experiments, rats were randomly assigned to one of four groups (n=l2/group)
·comprising a two (vehicle or antagonist) x two (vehicle or 3.0 mg/kg quinpirole) factorial design.
During the repeated treatment phase of the experiments, each rat was injected with vehicle or
antagonist and returned to its home cage. Fifteen min~tes later, each rat was injected with vehicle
or quinpirole and again returned to its home cage. Fifteen minutes after the second injection, the rat
w.as placed in the activity drum and activity was measured for 20 minutes. This procedure was
repeated daily for 8-10 ·days. The dose of SCH 23390 used in Experiment 2 was 0.5 mg/kg and
the dose of eticlopride used in Experiment 3 was 1.0 mg/kg. As in Experiment 1, twency-four
hours following the last drug treatment all rats were given 100 mg/kg NSD-1015 and were
sacrificed 30 minutes later.

Data analysis
For Experiment 1, locomotor activity .(activity counts pe( 20 minute session) and DOPA
accumulation (µg/g tissue) were each analyzed with a mixed factorial analysis of variance
(ANOVA) with drug as the between-subjects factor and day o~ brain region as the within-subjects
factor. For Experiments 2 and 3, locomotor activity and DOPA accumulation were each analyzed
with 2 x 2 mixed factorial ANOV As with the between-subjects factors as antagonist versus vehicle
and quinpirole versus vehicle treatment. The within-subjects factors were day or. brain regions.
Violations of homogeneity of variance were examined using the Huyn-Feldt epsilon. Degrees of
freedom were corrected if the epsilon value was< 0.75. Multiple comparisons were made using
the Dunnett's test comparing drug groups to the vehicle control or Student's t-tests. ,For the
ANOVAs and multiple comparisons, the alpha level was constrained to p .::;; 0.05.
For presentation purposes, DOPA accumulation data appear in graphs as the percent of the
baseline control values. The SEM values in the graphs are the percent SEM of the corresponding
I

group means. All data analyses were on the non-transformed data.
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RESULTS
Experiment 1
Locomotor activity
The locomotor activity data for the 8 days of repeated quinpirole treatment are shown in
Figure 1. A mixed factorial ANOVA revealed a significant main effect of day, F(7,252)=8.84,
p<0.0001, and a significant drug dose x day interaction, F(l4,252)=10.23, p<0.0001. An
ANOVA performed on day 8 data revealed a significant effect of drug dose, F(2,36)~.20,
p<0.05; however, Dunnett's tests did not reveal significant differences of the two doses compared
to the vehicle coritrols.
DOPA Accumulation
For the control groups, the mean DOPA levels.± SEM across the three experiments were
(in µgig tissue): 1.20 + 0.11 for striaturn, 0.82 ± 0.20 for NAOT and 0.30 ± 0.04 for VM. The
DOPA accumulation results of Experiment l are shown in Figure 2. A mixed factorial ANOVA
revealed a significant main effect of region, F(2, 72)=209.9, p<0.0001 and a significant region x
quinpirole dose interaction, F(4,72)=3.06, p<0.05. Multiple comparisons revealed that DOPA
levels in the striatum were significantly elevated at both doses of quinpirole compared to control
. (Dunnett's tests, p<0.05).
Experiment 2
Locomotor activity
The locomotor activity data for the 8 days of repeated quinpirole-SCH 23390 treatment are
shown in Figure 3. A mixed factorial ANOVA revealed the following significant between-subjects
effects: quinpirole main effect, F(l,44)=15.22, p<0.001; SCH 23390 main effect,
F(l,44)=272.27, p<0.0001; quinpirole x SCH 23390 interaction, F(l,44)=22.65, p<0.0001. The
following effects involving repeated measures were significant day main effect, F(7,308)=13.77,
p<0.0001; quinph-ole x day interaction, F(7,308)=25.87, p<0.0001; SCH 23390 x 'day
interaction, F(7,308)=10.69, p<0.0001; quinpirole x SCH 23390 x day interaction;
F(7,308)=17.68, p<0.0001. The significant overall interaction likely reflects the gradual increase
to control levels by rats treated with vehicle and quinpir9le, while all other groups did not change
across days. An ANOVA perforined on day 8 revealed a significant main effect of SCH 23390,
F(l,44)=194.42, p<0.0001. The main effect of quinpirole treatment approached, but did not
achieve significance, F(l,44)=3.77, p=0.0586. The interaction of quinpirole and SCH 23390 and
all multiple comparisons on day 8 were not significant.
7

...

DOPA accumulation
The DOPA accumulation results for the three braill regions are shown in Figure 4. A mixed
factorial ANOVA revealed significant ffiain effects of quinpirole treatment, F(l,44)=14.08,
p<0.001, and region, F(2,88)=385.41, p<0.0001 (epsilon=0.62). The interaction of region x
I

quinpirole treatment also was significant, F(2,88)=12.32, p<0.001 (epsilon=0.62). No maill effect
or interaction involving SCH 23390 treatment was significant, suggesting that SCH 23390 cotreatment was without effect on DOPA accumulation. Indeed, multiple comparisons revealed that
DOPA levels in the vehicle-quinpirole and SCH 23390-quinpirole treated rats were significantly
greater than control in both striatum and NAOT (Dunnett's tests, p<0.05). Comparisons of DOPA
levels in striatum and NAOT of the vehicle-quinpirole and SCH 23390-quinpirole rats revealed no
significant difference (Student's t-test, p<0.05).

Experiment 3
Locomotor activity
The locomotor activity data for the 10 days of repeated quinpirole-eticlopride treatment are
shown in Figure 5. A mixed factorial ANOVA revealed a significant between-subjects maill effect
of eticlopride, F(l,44)=98.55, p<0.0001, only. The following effects involving repeated
measures were significant: day maill effect, F(9,396)=4.95, p<0.0001; quinpirole x day
interaction, F(9,396)=13,36, p<0.0001; eticlopride x day interaction, F(9,396)=3.35, p<0.001;
quinpirole x eticlopride x day interaction, F(9,396)=5.25, p<0.0001. An ANOVA performed on
day 10 revealed a significant main effect of quinpirole, F(~,44)=7. 77, p<O.O 1, and of eticlopride,
F(l,44)=41.48, p<0.0001. The interaction of quinpirole and SCH 23390 on day 10 was not
significant Dunnett's tests showed that the group treated with quinpirole and vehicle jlad
significantly greater locomotor activity counts than the vehicle control group (p<0.05). In addition,
both groups treated with eticlopride showed significantly lower locomotor activity counts than the
controls (p<0.05).

DOPA accumulation
The DOPA accumulation results for the three brain regions are shown in Figure 6. A mixed
factorial ANOVA revealed a significant main effect of region, F(2,86)=87 .72, p<O:OOO 1
(epsilon=0.68). No other main effects or interactions were significant. The interactio~ of
quinpirole treatment and eticlopride treatment approached, but did not achieve signifidance,
F(l,46)=3.85, p=0.056. As in Experiment 2, multiple comparisons showed that DOPA
accumulation was significantly increased in vehicle-quinpirole treated rats compared to controls in

8

•.·

both the striatum and NAOT (Dunnett's tests, p<0.05). Comparisons between controls and the
eticlopride-quinpirole treated rats revealed a significant increase in DOPA accumulation for the
striatum, but not NAOT (Dunnett's tests, p<0.05). However, DOPA levels als,o were elevated in
the eticlopride-vehicle treated rats compared to controls in both striatum and NAOT (Dunnett's
tests, p<0_.05). Additional t-tests comparing eticlopride-vehicle and eticlopride-quinpirole rats
revealed no significant differences.

DISCUSSION
Consistent with our previous findings, acute quinpirole treatment resulted in dosedependent suppression of locomotor activity (Mattingly et al., 1993). With repeated treatment, the
locomotor suppressant effect of quinpirole diminished until the locomotor activity levels were the
same as the vehicle controls. This tolerance effect also is consistent with previous findings from
our laboratory (Mattingly et al., 1993). Interestingly, a trend for an increase in locomotor activity
compared to controls in rats treated with repeated quinpirole was evident in Experiment 1 on day 8.
In Experiment 3, this locomotor activiting effect achieved significance after 10 days of treatment
This finding may be indicative of a weak locomotor sensitization effect that occurs subsequent to
the development of tolerance to the locomotor suppressant effects of quinpirole. Indeed, repeated
treatment with 3.0 mg/kg of quinpirole resulted in cross-sensitization to apomorphine (Mattingly et
al., 1993), and sensitization to the locomotor effects of quinpirole, as well as the D1 agonist
. bromocriptine, has been reported {Eilam and Szechtman, 1990; Hoffman and Wise, 1992).
The major finding of the present experiment was that repeated quinpirole treatment resulted
in enhanced DOPA accumulation in the striatum and NAOT. Thus, consistent with previous
studies with repeated apomorphine treatment (Rowlett et iil·· 1991, 1993; Vaughn et al., 1990),
repeated stimulation of D1 type dopamine receptors resulted in enhanced dopamine synthesis in
dopamine terminal fields. Using meta-analytic techniques, we have previously noted that enhanced
dopamine synthesis in the NAOT following repeated apomorphine treatment may be a relatively
weak effect compared to the effect obtained in the striatum (Rowlett et al., 1993). Some evidence
for a similar relationship between dopamine synthesis in the NAOT and striaturn following
repeated quinpirole was obtained in the present series of experiments. Thus, while striatal
dopamine synthesis was clearly increased in all three experiments, the enhanced dopamine
synthesis effect was obtained in the NAOT only in Experiments 2 and 3, ·but not Experiment 1.
Moreover, the magnitude of the percentage increase in DOPA accumulation in the NAOT varied
from experiment to experiment, whereas the magnitude of the percentage increase Ui DOPA
accumulation in the striatum was relatively consistent across experiments. The reason for this
difference in DOPA accumulation results between the striatum and NAOT is not clear; however,
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the results may reflect a clifferential modulation of dopamine synthesis between the striatum and
NAOT.
Experiment 2 demonstrated that co-administration of the selective D1 receptor antagonist
SCH 23390 did nbt block the enhanced dopamine synthesis effect produced by repeated quinpirole
treatment This finding is consistent with modulation of dopamine synthesis by D1 autoreceptors,
and not Di-type receptors (Brown et al., 1985; Wachtel et al., 1989; White and Wang, 1984b;
Wolf and Roth, 1990). Further, this finding is consistent with a previous study which indicated
that Di receptor stimulation does not result in enhanced dopamine synthesis (Rowlett et al., 1993).
The results of Experiment 3 suggest that the D1-type antagonist eticlopride blocked the enhanced
dopamine synthesis effect produced by quinpirole in the NAOT. This finding is consistent with
eticlopride's high selectivity for D1-type receptors and provides further evidence for D1-type
modulation of the enhanced dopamine synthesis effect In the striatum, there was no significant
clifference in DOPA accumulation between the eticlopride-vehicle and eticlopride-quinpirole treated
rats, also suggestive of a blockade of the enhanced dopamine synthesis effect produced by repeated
quinpirole treatment However, dopamine synthesis was enhanced following repeated eticlopride
treatment in both striatum and NAOT. This finding was unexpected and the reason for this
enhanced dopamine synthesis effect following repeated eticlopride treatment is not clear. One
possibility is that eticlopride was present in the brain at the time of NSD-1015 administration.
Support for this notion comes from previous findings that acute eticlopride treatment produces
enhanced DOPA accumulation (Tylor and Galloway, 1992) and D2"type antagonists produce
enhanced dopamine neuron impulse flow (White and Wang, 1986). Indeed, O'Dell et al. (1993)
reported that repeated eticlopride treatment (4 injections at 2-hour intervals) resulted in enhanced
striatal dopamine release, measured with .in vivo microdia\ysis. It is also possible, however, that
repeated eticlopride treatment resulted in some neurochemical alteration that indirectly enhanced
'.
dopamine synthesis. For example, repeated eticlopride treatment results in up-regulation of D1-type
receptors (LaHoste and Marshall, 1991); however, up-regulation of autoreceptors would likely
result in decreased dopamine synthesis. These issues clearly require further investigation;
nevertheless, evidence for a blockade of repeated quinpirole-induced enhanced dopamine synthesis
in the NAOT clearly was obtained, in spite of the increase in DOPA accumulation produced by
repeated eticlopride alone.
The observation of an enhanced dopamine synthesis effect after repeated quinpirole
treatment is consistent with the notion that repeated non-selective dopamine agonist treatment
produces a reduction in dopamine autoreceptor sensitivity (e.g:, Henry et al., 1989; Jeziorski and
White 1989; Rebec and Lee, 1982; Rowlett et al., 1991, 1993; White and Wang, 1984a). Indeed,
the results of this study combined with our previous findings indicate that the enhanced dopamine
synthesis effect observed after repeated apomorphine treatment likely is modulated by D2-type
10
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autoreceptors. Taken together, our findings are consistent with an hypothesis for the development
of behavioral sensitization advanced by Henry et aL (1989). Specifically, these authors suggested
that repeated cocaine treatment results in subsensitivity of impulse-regulating autoreceptors
followed by terminal field D 1 receptor supersensitivity. The results of the present study and our
previous study (Mattingly et al., 1993) showing cross-sensitization of quinpirole and apomorphine
that was blocked by a Di antagonist are consistent with this hypothesis. Thus, repeated quinpirole
treatment may result in autoreceptor subsensitivity, which in tum results in enhanced dopamine
release and consequent D1 stimulation. In the present study, blockade of Di receptors had no effect
on dopamine synthesis after repeated quinpirole treatment. Therefore, autoreceptor subsensitivity
may occur without the development of locomotor sensitization.
Recent molecular biological studies have identified at least five subtypes of dopamine
receptors (see Schwartz et al., 1993). Of these subtypes, quinpirole binds with higher affinity to
the D3 subtype than to the Di or D4 subtypes, whereas apomorphine is relatively non-selective for
the D2 subtypes (Levesque et al., 1992; Sokoloff et al.,.1990; Van Toi et al., 1991). Based upon
this affinity difference, it may be speculated that the enhanced dopamine synthesis effect observed

after repeated quinpirole and apomorphine treatment may involve repeated D3 receptor stimulation.
However, it is not known if the doses used in the present study differentiate between the the two
subtypes. In addition, the most robust augmentation of dopamine synthesis occurred in the
striatum, an area that has low levels of D3 mRNA, as well as low binding levels of the D3 ligand
(3H]7-0H-DPAT (Levesque et al.; 1992; Sokoloff et al., 1990; see Schwartz et al., 1993). Thus,
the role of D3 versus D2· receptors in the enhanced dopamine synthesis effect remains to be
determined.
Finally, another possible mechanism of enhanced dqpamine synthesis following repeated
apomorphine treatment involves an alteration of tyrosine hydroxylase activity. Apomorphine, in
addition to having dopamine receptor binding properties, also may be carried into dopamine
neurons where it inhibits tyrosine hydroxy lase activity directly at the pteridine cofactor site
(Laschinski et al., 1984). Based on the results of the present study, however, this effect of
apomorphine may not be involved in the enhanced dopamine synthesis effect because quinpirole
does not have a catechol structure (Titus et al., 1983). Thus, any changes in tyrosine hydroxylase
activity following repeated D2 agonist treatment are likely due to an indirect influence on the
enzyme rather than direct drug-induced changes at the pteridine cofactor siie.
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Figure 1.

FIGURE CAPTIONS
Activity counts (mean± SEM) per 20-min session across the 8 days of
treatment with quinpirole or vehicle (n=13 rats/group).

Figure 2.

DOPA accumulation (mean percent of vehicle control in µg/g ±percent SEM for
each group) for rats treated 8 days with quinpirole or vehicle (n=13/group). All rats
were treated with NSD-1015 (100 mg/kg) on day 9 prior to dissection of the
striatum, NAOT (nucleus accumbens-olfactory tubercle) and VM (ventral
mesencephalon). Note that"*" indicates a significant difference from control
(Dunnett's test, p<0.05).

Figure 3.

Activity counts (mean ± SEM) per 20-min session across the 8 days of
treatment with combinations of quinpirole (QUIN, 3.0 mg/kg), SCH 23390 (SCH,
0.5 mg/kg) or vehicle (VEH; n=12 rats/group).

Figure 4.

DOPA accumulation (mean percent of vehicle control in µg/g ±percent SEM for
each group) for rats treated 8 days with combinations of quinpirole (QUIN, 3.0
mg/kg), SCH 23390 (SCH, 0.5 mg/kg) or vehicle (YEH; n=l2/group). All rats ,
were treated with NSD-1015 (100 mg/kl:l) on day 9 prior to dissection of the
striatum, NAOT (nucleus accumbens-olfactory tubercle) and VM (ventral
mesencephalon). Note that "*" indicates a significant difference from control
(Dunnett's test, p<0.05).

Figure 5.

Activity counts (mean± SEM) per 20-min session across the 10 days of
~atment with combinations of quinpirole (QUIN, 3.0 mg/kg), eticlopride (ETIC,
1.0. mg/kg) or vehicle (YEH; n=12 rats/group).

Figure 6.

DOPA accumulation (mean percent of vehicle control in µg/g ±percent SEM for
each group) forrats treated 10 days with combinations of quinpirole (QUIN, 3.0
mg/kg), eticlopride (ETIC, 1.0 mg/kg) or vehicle (YEH; n=l2/group). All rats
were treated with NSD-1015 (100 mg/kg) on day 11 prior to dissection of the
striatum, NAOT (nucleus accumbens-olfactory tubercle) and VM (ve~tral
mesencephalon). Note that "*" indicates a significant difference from control
(Dunnett's test, p<0.05).

16

::

..
2000
I

:; (/) . 1800
. i I; ~ 1600

' 8.

•- - -e

0.3 MG/KG QUINPIROLE
0·------- 0 . VEHICLE

>
Iu
<(
z<(

1000

.--•1

9-.... -.. -

Q._____

-

800
600
.

400

..

I

.

·-o--------IT'I.------·------.rh
'+' --~--------

/._ - -·-. -

.

-

I
.
.
/
l
~/

T
•
.--- t

.
-

T

T

T

1200

~

3~0 MG/KG QUINPIROLE

•

1400

~

w

•

••/-

: .
~

.

.

!- -

-·l

-·

l

i

·-----

--9

--- l -- .•
l

.I.
.

200

.....

o---~--_._

1

__..___.___

·2 - 3

_ . L _ _ _~_._ _ _

4 5· -6 - 7-'
0 AYS

_i,___,

-s-

·:
'·

3.0 MG/KG QUINPIROLE
J®¢i 0.3 MG/KG QUINPIROLE
I I VEHICLE
W

I

..

150

I
)

~

c

·-00
+-'

'

-::J .............
0
L
100
E +-'
c
::J
()
()

:<(
<(

a...
0

0

0

()

~

'-/
.-;•

50

..

·'

.

.

.

-----------Str-1atum- __ c ___ ----NA0TRegion

------ --VM--

-- - - - - - -- -

-----

-

.... "Sll.··v.- -:.·--· •

MEAN ACTIVllY COUNTS
OJ
0,
0

........

........

........

0
0
0

N
0
0

~-

.........

en

.OJ
0
0

0
0

O•D•

VJ

1-Q-1
•
••

.

.•• ••.·

'
~oi
••
•

o~
)>

-<
(J)

0
0

........

. :. I :.
•
••

•

.

•
•••

O•D•
< < (/) (/)

rrirrioo

:r: :r: :r: :r:
I I I I

-<O<o
rricrric
:r:-:r:z z

()1

. '-J'
:

'

aJ'

...

,I

..
,,

CJ VEH - VEH

VEH- QUIN
[X] SCH - VEH
·~SCH - QUIN
~

I

150

·,
1

•
>

*

i:I

0

•.-4

.

~

,......._

r-4

r-4

aj

;:j

s

0

J-i

~

;:j

i:I

CJ
CJ

CJ

<
<
!lo!
0

100

0

~
..__.,

50

i::l

---- Str-iatum

- - NAOT
Region

-vM

,I

..
1800

(f)

I
·,

I-

1600

~z

:::::J·

~

.;

1400

0

u
~
>·
-

'

1200
1000

I-

800

<(

600

z<(

400

w

.LOO

~

0
-

-- -

--

0.
- ·. ·.

-

O······O.
-

.,. T

T

.

•••

T /

- ..

/_J.

1\.

e

l

l

. ··o·-···-e:i:
--•
l. .. ----0······0······0
.
······(!)···· .. t:J
.
............. I

D

e

T/~

/

T

·--·
T

0

-

• •
• ••

ETIC - QUIN
D········ D ETIC :-- VEH
VEH ~QUIN
O········ 0 VEH - VEH

T .

.•

............

T

T

3

4·

5

/ . l '-.... .T

T

T

:7!=~<:~><6::i!-·-'--o---'·~::::~=:::~
.1

2

6

DAYS

7 . 8 --9 . 10' -

,.
>'

·:
"

Striatum

-- NAOT .

Region

FtG.lf

